Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers

Fineline Cube Oct 20, 2025

Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...

Company Deals

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Fineline Cube Oct 20, 2025

Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite,...

Company Deals

Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment

Fineline Cube Oct 17, 2025

Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced on October 17, 2025, that its subsidiary, AskGene...

Company Drug

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer

Fineline Cube Oct 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...

Company Drug

Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device

Fineline Cube Oct 17, 2025

Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...

Company Deals

Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide

Fineline Cube Oct 17, 2025

Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...

Company Medical Device

Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device

Fineline Cube Oct 17, 2025

Sinclair (Hangzhou) Medical Technology Co., Ltd., a wholly‑owned subsidiary of Huadong Medicine (SHE: 000963), announced...

Company Deals

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101

Fineline Cube Oct 17, 2025

I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...

Company Drug

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC

Fineline Cube Oct 17, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...

Company Deals

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia

Fineline Cube Oct 17, 2025

Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...

Company Deals

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates

Fineline Cube Oct 17, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...

Company Deals

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110

Fineline Cube Oct 17, 2025

Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial

Fineline Cube Oct 17, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...

Company

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up

Fineline Cube Oct 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...

Company Deals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

Fineline Cube Oct 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...

Company Deals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Fineline Cube Oct 16, 2025

China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...

Company Drug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Fineline Cube Oct 16, 2025

Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...

Company Drug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC

Fineline Cube Oct 16, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...

Company Deals

Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital

Fineline Cube Oct 16, 2025

Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...

Policy / Regulatory

Zhejiang Authority Imposes Administrative Penalties on Dahongying Pharma for Substandard Fluorouracil Injection

Fineline Cube Oct 16, 2025

The Zhejiang Provincial Medical Products Administration announced that Ningbo Dahongying Pharmaceutical Co., Ltd. has been...

Posts pagination

1 … 88 89 90 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.